Results 71 to 80 of about 15,580 (201)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 231-241, January 2026.
We evaluated long‐term outcomes following nucleos(t)ide analogue discontinuation in HBeAg‐negative chronic hepatitis B. HBsAg loss was infrequent. Early HBsAg loss occurred in patients with low end‐of‐treatment HBsAg levels and without ALT flare, whilst late HBsAg loss typically followed ALT flares and was associated with higher end‐of‐treatment HBsAg ...
Simon J. Hume, Samuel Hall, Gareth Burns, Sara Vogrin, Daniel Tassone, Paul Desmond, Dilip Ratnam, Miriam T. Levy, Rohit Sawhney, Amanda Nicoll, Zina Valaydon, Simone I. Strasser, Meng Ngu, Marie Sinclair, Chris Meredith, Gayle V. Matthews, Kumar Visvanathan, Jacinta A. Holmes, Alexander J. Thompson   +18 more
wiley   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B [PDF]

, 2013
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98397/1/apt12344 ...
Beasley, Bruix, Chen, El-Serag, Fattovich, Fattovich, Fattovich, Fattovich, Fattovich, Heathcote, Hosaka, Inoue, Kobashi, Koklu, Lai, Liaw, Liaw, Lok, Papatheodoridis, Papatheodoridis, Sherman, Simonetti, Singal, Ulm, Yang, Yang   +25 more
core   +1 more source

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 254-263, January 2026.
Hepatitis B immunoglobulins withdrawal in hepatitis B virus mono‐infected liver transplant recipients: An Italian multicentre prospective study. ABSTRACT Background & Aims Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside ...
Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone, Monica Cucco, Marco Carbone, Donatella Cocchis, Elisa Farina, Luisa Pasulo, Mauro Viganò, Michele Sagasta, Elisabetta Degasperi, Davide Ghinolfi, Pietro Lampertico, Stefano Fagiuoli, Luca Saverio Belli, on behalf of the INSIGHT‐B study group   +24 more
wiley   +1 more source

Entecavir-Associated Thrombocytopenia: A Case Report and Review of the Pathophysiology, Diagnosis, and Treatment of a Rare but Reversible Cause of Thrombocytopenia

Case Reports in Hematology, 2019
Drug-associated thrombocytopenia is often unrecognized. We report a 76-year-old female with lymphoma who presented with easy bruising and oral bleeding. She had undergone screening for hepatitis B virus (HBV) prior to starting rituximab and was found to ...
Binoy Yohannan, Dai Chu N. Luu, Mark Feldman   +2 more
doaj   +1 more source

Effect and safety analysis of Yiqi Yangxue Jiedu decoction combined with entecavir in the treatment of male patients with decompensated hepatitis B cirrhosis [PDF]

Journal of Men's Health
Background: This study aimed to evaluate the efficacy and safety of Yiqi Yangxue Jiedu Decoction & Entecavir in male patients with decompensated hepatitis B cirrhosis.
Mingli Jia
doaj   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients

The Saudi Journal of Gastroenterology, 2015
Background/Aims: This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naïve CHB patients. Patients and Methods: We performed a retrospective cohort study of treatment-naive CHB patients who
Hyung Min Yu, So Young Kwon, Jiwan Kim, Hyun Ah Chung, Se Woong Kwon, Taek Gun Jeong, Sang Hee An, Gyung Won Jeong, Seon Ung Yun, Jae Ki Min, Jeong Han Kim, Won Hyeok Choe   +11 more
doaj   +1 more source

Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Oncology patients receiving cytostatic therapy used to be at high risk of HBV infection when HBV screening measures were less reliable. Infections acquired under these conditions often persist, like those acquired perinatally or during early infancy.
Thomas Baumgarten, Felix Lehmann, Tina Senff, Heiko Slanina, Christian G. Schüttler, Andreas Walker, Wolfram H. Gerlich, Reinald Repp, Jörg Timm, Dieter Glebe, Markus Metzler   +10 more
wiley   +1 more source

Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation [PDF]

, 2011
Without any treatment, the prognosis of hepatitis B in liver transplant recipients is very poor. So, antiviral prophylaxis is very important in patients with hepatitis B who undergo liver transplantation. Before liver transplantation, a suppression of
D'Avola, D. (Delia), Herrero, J.I. (José Ignacio)   +1 more
core   +1 more source